CG
NGNE icon

Cutler Group’s Neurogene NGNE Stock Holding History

Cutler Group’s Portfolio NGNE Stock Details NGNE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q4 		– Sell
-165
Closed -$1K – 4386
2018
Q3 		$1K Buy
165
+90
+120% +$5.31K ﹤0.01% 3819
2018
Q2 		$15K Buy
75
+25
+50% +$6.52K ﹤0.01% 2388
2018
Q1 		$2K Buy
+50
New +$13.8K ﹤0.01% 3789
2017
Q3 		– Sell
-230
Closed -$2K – 6414
2017
Q2 		$2K Sell
230
-3,860
-94% -$1.1M ﹤0.01% 5567
2017
Q1 		$10K Buy
4,090
+2,765
+209% +$971K ﹤0.01% 4040
2016
Q4 		$29K Buy
1,325
+1,220
+1,162% +$328K ﹤0.01% 3087
2016
Q3 		$1K Buy
+105
New +$21.2K ﹤0.01% 6210

Other funds holding NGNE

BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
OM
Opaleye Management Boston, Massachusetts $759M AUM 124.8% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Cutler Group's NGNE Position: Q3 2019 in Review

Cutler Group sold out of Neurogene (NGNE) in Q3 2019, closing a stake of 150 shares — an estimated $7K sold.

Cutler Group first reported a position in NGNE in Q3 2016 and held it in 12 quarters. The position peaked at $68K in Q3 2016. 36 funds tracked by Wall St. Rank hold NGNE as of Q3 2019.

  • Cutler Group reported no remaining Neurogene position as of Q3 2019 after selling out during the quarter.
  • Cutler Group sold 150 Neurogene shares in Q3 2019, an estimated $7K.
  • Cutler Group first reported a position in Neurogene in Q3 2016 and held it in 12 quarters.
  • Cutler Group's Neurogene position peaked at $68K in Q3 2016.
  • 36 funds tracked by Wall St. Rank held Neurogene as of Q3 2019.

Based on Cutler Group's 13F filing for Q3 2019, filed 28 Oct 2019.